Prostate Cancer Clinical Trial

Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

Summary

The purpose of this study is to evaluate the incidence of urinary and gastrointestinal acute and late side effects in patients treated with stereotactic body radiotherapy (SBRT) to the prostate. Stereotactic radiation therapy is given as five treatments over a 2-3 week period. The prostate is localized and the plan is reoptimized as needed prior to each treatment.

View Full Description

Full Description

This protocol requires radiation treatments to be performed with a stereotactic technique with the use of a 3-D coordinate system defined by implanted transponders (i.e. Calypso) or use of the ExacTrac system and/or use cone-beam CT (CBCT) with fiducial markers.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed diagnosis of adenocarcinoma of the prostate within 365 days of study enrollment
History/physical examination with digital rectal examination of the prostate within 8 weeks prior to study enrollment
Gleason score less than or equal to 7
Clinical Stage T1-T2c
PSA
less than or = 15 ng/ml prior to start of therapy if Gleason < or = 6 or
less than or = 10 ng/ml prior to start of therapy if Gleason = 7
Zubrod Performance Status 0-1
Age > 40

Exclusion Criteria:

Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years. (Carcinoma in situ of the bladder or oral cavity is permissible)
Evidence of distant metastases
Regional lymph node involvement
Significant urinary obstruction
Estimated prostate gland > 100 grams
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Previous hormonal therapy, such as LHRH agonists (e.g. goserelin, leuprolide), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., DES), or surgical castration (bilateral orchiectomy) or planned concurrent androgen deprivation therapy
Previous or concurrent cytotoxic chemotherapy for prostate cancer
Prosthetic implants in the pelvic region that contain metal or conductive materials (e.g., an artificial hip).
Severe, active comorbidity

Study is for people with:

Prostate Cancer

Estimated Enrollment:

60

Study ID:

NCT00941915

Recruitment Status:

Completed

Sponsor:

Duke University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Duke University Medical Center
Durham North Carolina, 27710, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

60

Study ID:

NCT00941915

Recruitment Status:

Completed

Sponsor:


Duke University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider